Onpattro
Alnylam gives up on Onpattroās US expansion after FDA rejects its rare heart disease indication
Anika Sharma
Despite receiving an endorsement from an advisory committee, the FDA has reached a different conclusion regarding the benefit-risk profile of ...
FDA panel backs Alnylamās Onpattro for rare heart condition despite small benefit
Anika Sharma
After facing doubts from the FDA regarding the expansion of its RNA-silencing drug Onpattro into the treatment of transthyretin amyloidosis ...
FDA doubts Onpattroās benefit in heart disease, Alnylam faces Pfizer hurdle
Anika Sharma
The FDA has raised significant concerns about Alnylam’s attempt to expand the use of Onpattro for the treatment of transthyretin ...
